{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:35:03Z","timestamp":1756463703741},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"DOI":"10.7759\/cureus.60435","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T15:34:22Z","timestamp":1715873662000},"source":"Crossref","is-referenced-by-count":1,"title":["Stroma-Rich Hyaline Vascular Type of Castleman Disease: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Ranim F","family":"Al Derbas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A","family":"Al Nafisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad T","family":"Al Khiary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah S","family":"Al Ghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadel Z","family":"Al Oatibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020, 135:1353-64. 10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328186ffab","article-title":"Castleman disease","volume":"14","author":"Dham A","year":"2007","unstructured":"Dham A, Peterson BA. Castleman disease. Curr Opin Hematol. 2007, 14:354-9. 10.1097\/MOH.0b013e328186ffab","journal-title":"Curr Opin Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone A","year":"2021","unstructured":"Carbone A, Borok M, Damania B, et al.. Castleman disease. Nat Rev Dis Primers. 2021, 7:84. 10.1038\/s41572-021-00317-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-8-199804150-00010","article-title":"The clinical behavior of localized and multicentric Castleman disease","volume":"128","author":"Herrada J","year":"1998","unstructured":"Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998, 128:657-62. 10.7326\/0003-4819-128-8-199804150-00010","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2016.05.006","article-title":"Multicentric Castleman disease: where are we now?","volume":"33","author":"Wang HW","year":"2016","unstructured":"Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: where are we now?. Semin Diagn Pathol. 2016, 33:294-306. 10.1053\/j.semdp.2016.05.006","journal-title":"Semin Diagn Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20\u00a0years","volume":"180","author":"Oksenhendler E","year":"2018","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D, et al.. The full spectrum of Castleman disease: 273 patients studied over 20\u00a0years. Br J Haematol. 2018, 180:206-16. 10.1111\/bjh.15019","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF01607150","article-title":"Morpho-immunophenotypic diversity of Castleman's disease, hyaline-vascular type: with emphasis on a stroma-rich variant and a new pathogenetic hypothesis","volume":"423","author":"Danon AD","year":"1993","unstructured":"Danon AD, Krishnan J, Frizzera G. Morpho-immunophenotypic diversity of Castleman's disease, hyaline-vascular type: with emphasis on a stroma-rich variant and a new pathogenetic hypothesis. Virchows Arch A Pathol Anat Histopathol. 1993, 423:369-82. 10.1007\/BF01607150","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23657","article-title":"Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome","volume":"47","author":"Jakub\u00edkov\u00e1 M","year":"2013","unstructured":"Jakub\u00edkov\u00e1 M, Pi\u0165ha J, Latta J, Ehler E, Schutzner J. Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome. Muscle Nerve. 2013, 47:447-51. 10.1002\/mus.23657","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.930948","article-title":"A case report of subclinical myasthenia gravis associated with Castleman\u2019s disease","volume":"22","author":"Adil Alsinan T","year":"2021","unstructured":"Adil Alsinan T, Ahmad Robaidi H, Neamatallah Saleh W. A case report of subclinical myasthenia gravis associated with Castleman\u2019s disease. Am J Case Rep. 2021, 22:e930948. 10.12659\/AJCR.930948","journal-title":"Am J Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03494-2","article-title":"Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases","volume":"147","author":"Sun DP","year":"2021","unstructured":"Sun DP, Chen WM, Wang L, et al.. Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases. J Cancer Res Clin Oncol. 2021, 147:2107-15. 10.1007\/s00432-020-03494-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1008587","article-title":"Case report: the stroma-rich variant of Castleman's disease of hyaline-vascular type with atypical stromal cell proliferation and malignant potential: An exceptional rare case occurred in mediastinal lymph node","volume":"13","author":"Shi X","year":"2023","unstructured":"Shi X, Liao M, Yin X, Chen Y, Huang C, Yin W, Li J. Case report: the stroma-rich variant of Castleman's disease of hyaline-vascular type with atypical stromal cell proliferation and malignant potential: An exceptional rare case occurred in mediastinal lymph node. Front Oncol. 2023, 13:1008587. 10.3389\/fonc.2023.1008587","journal-title":"Front Oncol"},{"key":"ref12","article-title":"A rare stroma-rich variant of hyaline-vascular Castleman\u2019s disease associated with calcifying fibrous pseudotumor","volume":"8","author":"Ma H","year":"2015","unstructured":"Ma H, Jiang M, Xiao W. A rare stroma-rich variant of hyaline-vascular Castleman\u2019s disease associated with calcifying fibrous pseudotumor. Int J Clin Exp Pathol. 2015, 8:3362-4.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.006","article-title":"Unicentric Castleman disease","volume":"32","author":"Wong RS","year":"2018","unstructured":"Wong RS. Unicentric Castleman disease. Hematol Oncol Clin North Am. 2018, 32:65-73. 10.1016\/j.hoc.2017.09.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15921","article-title":"Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases","volume":"186","author":"Boutboul D","year":"2019","unstructured":"Boutboul D, Fadlallah J, Chawki S, et al.. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019, 186:269-73. 10.1111\/bjh.15921","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee F","year":"2020","unstructured":"van Rhee F, Oksenhendler E, Srkalovic G, et al.. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020, 4:6039-50. 10.1182\/bloodadvances.2020003334","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010801)92:3<670::aid-cncr1369>3.0.co;2-q","article-title":"Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy","volume":"92","author":"Chronowski GM","year":"2001","unstructured":"Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001, 92:670-6. 10.1002\/1097-0142(20010801)92:3&lt;670::aid-cncr1369&gt;3.0.co;2-q","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman disease","volume":"32","author":"Wu D","year":"2018","unstructured":"Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease. Hematol Oncol Clin North Am. 2018, 32:37-52. 10.1016\/j.hoc.2017.09.004","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-351","article-title":"Multicentric Castleman disease and the evolution of the concept","volume":"113","author":"Zhou T","year":"2021","unstructured":"Zhou T, Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease and the evolution of the concept. Pathologica. 2021, 113:339-53. 10.32074\/1591-951X-351","journal-title":"Pathologica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1066896908315812","article-title":"Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases","volume":"16","author":"Kojima M","year":"2008","unstructured":"Kojima M, Nakamura N, Tsukamoto N, et al.. Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol. 2008, 16:391-8. 10.1177\/1066896908315812","journal-title":"Int J Surg Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19990201)85:3<706::aid-cncr21>3.0.co;2-7","article-title":"The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature","volume":"85","author":"Bowne WB","year":"1999","unstructured":"Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999, 85:706-17. 10.1002\/(sici)1097-0142(19990201)85:3&lt;706::aid-cncr21&gt;3.0.co;2-7","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy","volume":"6","author":"Mukherjee S","year":"2022","unstructured":"Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022, 6:359-67. 10.1182\/bloodadvances.2021004441","journal-title":"Blood Adv"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto N","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008, 112:3959-64. 10.1182\/blood-2008-05-155846","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15138","article-title":"Paraneoplastic pemphigus associated with Castleman disease: a multicenter case series","volume":"40","author":"Barry KK","year":"2023","unstructured":"Barry KK, Plumptre I, Bazewicz CG, et al.. Paraneoplastic pemphigus associated with Castleman disease: a multicenter case series. Pediatr Dermatol. 2023, 40:90-5. 10.1111\/pde.15138","journal-title":"Pediatr Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05659.x","article-title":"Paraneoplastic pemphigus in association with Castleman's disease","volume":"149","author":"Nikolskaia OV","year":"2003","unstructured":"Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol. 2003, 149:1143-51. 10.1111\/j.1365-2133.2003.05659.x","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13378","article-title":"Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor","volume":"169","author":"Dong Y","year":"2015","unstructured":"Dong Y, Wang M, Nong L, et al.. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol. 2015, 169:834-42. 10.1111\/bjh.13378","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa053","article-title":"Predominant stroma-rich feature in hyaline vascular variant of Castleman disease is associated with paraneoplastic pemphigus","volume":"154","author":"Wang L","year":"2020","unstructured":"Wang L, Nong L, Li F, et al.. Predominant stroma-rich feature in hyaline vascular variant of Castleman disease is associated with paraneoplastic pemphigus. Am J Clin Pathol. 2020, 154:403-13. 10.1093\/ajcp\/aqaa053","journal-title":"Am J Clin Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239668-stroma-rich-hyaline-vascular-type-of-castleman-disease-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T15:34:25Z","timestamp":1715873665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239668-stroma-rich-hyaline-vascular-type-of-castleman-disease-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.60435","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}